BRAF as a potential therapeutic target in melanoma and other malignancies
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 4 (2), 95-98
- https://doi.org/10.1016/s1535-6108(03)00189-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Mechanisms of regulating the Raf kinase familyCellular Signalling, 2002
- BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90Blood, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMACytokine, 2000
- Nerve Growth Factor-mediated Activation of the Mitogen-activated Protein (MAP) Kinase Cascade Involves a Signaling Complex Containing B-Raf and HSP90Journal of Biological Chemistry, 1996
- Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colonGastroenterology, 1995